Core Viewpoint - MaxCyte, Inc. (MXCT) is experiencing significant selling pressure, with a 30.2% decline over the past four weeks, but is now positioned for a potential trend reversal as it enters oversold territory, supported by analysts predicting better earnings than previously expected [1] Group 1: Technical Indicators - The Relative Strength Index (RSI) is utilized to determine if a stock is oversold, with a reading below 30 indicating oversold conditions [2] - MXCT's current RSI reading is 23.64, suggesting that the heavy selling may be exhausting itself and a trend reversal could be imminent [5] Group 2: Fundamental Analysis - There is strong consensus among sell-side analysts that MXCT's earnings estimates for the current year have increased by 19.7% over the last 30 days, indicating potential price appreciation [7] - MXCT holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, further supporting the stock's potential for a turnaround [8]

A downtrend has been apparent in Terns Pharmaceuticals, Inc. (TERN) lately with too much selling pressure. The stock has declined 39.8% over the past four weeks. However, given the fact that it is now in oversold territory and Wall Street analysts are majorly in agreement about the company's ability to report better earnings than they predicted earlier, the stock could be due for a turnaround.Guide to Identifying Oversold StocksWe use Relative Strength Index (RSI), one of the most commonly used technical in ...